Lupus is primarily a type 3 (type III) hypersensitivity reaction. The hallmark of the disease is the formation of immune complexes, clusters of antibodies bound to the body’s own nuclear material, that circulate in the blood and deposit in tissues like the kidneys, skin, and blood vessels. Once lodged there, these complexes trigger inflammation and tissue damage. That said, lupus is a complex disease that also involves type 2 hypersensitivity in certain manifestations, which is part of why it affects so many different organ systems.
How Type 3 Hypersensitivity Works in Lupus
In a type 3 hypersensitivity reaction, soluble antigens and antibodies combine in the bloodstream to form immune complexes. Normally, the body clears these complexes efficiently. In lupus, two things go wrong: the immune system produces antibodies against the body’s own cell components (autoantibodies), and the clearance system can’t keep up with the volume of complexes being generated.
The primary targets of these autoantibodies are nuclear materials, the DNA and proteins inside your own cells. Anti-nuclear antibodies (ANAs) are present in over 90% of lupus patients. The most clinically significant are antibodies against double-stranded DNA (anti-dsDNA), which serve as both a diagnostic marker and an active driver of organ damage. Other common targets include ribonucleic protein particles (anti-Ro, anti-La, anti-Sm) and histone proteins. When cells die through normal turnover or increased rates of cell death, these nuclear contents are released, and the autoantibodies bind to them, forming immune complexes containing nucleosomes and ribonucleic proteins.
These circulating complexes then deposit in tissues, particularly in the walls of small blood vessels and the filtering structures of the kidneys. Once deposited, they activate the complement system, a cascade of immune proteins that acts as an alarm. Complement activation draws in neutrophils and other inflammatory cells, which release enzymes like collagenase and elastase that directly damage tissue. This creates a self-reinforcing cycle: tissue damage releases more nuclear material, which forms more immune complexes, which causes more inflammation.
Why B Cells Drive the Process
The engine behind type 3 hypersensitivity in lupus is abnormal B cell behavior. B cells are the immune cells responsible for producing antibodies, and in lupus they malfunction in several ways. There’s an imbalance in B cell subtypes, with a disproportionate increase in memory B cells relative to naive B cells. Memory B cells have a lower activation threshold, meaning autoreactive ones can thrive with very little antigen contact. On top of that, B cells in lupus patients have exaggerated receptor responses. When their receptors are triggered, they show increased calcium influx and heightened signaling compared to healthy B cells.
This combination means B cells churn out autoantibodies targeting nuclear components at abnormally high rates. Making matters worse, some of these B cells mature into long-lived plasma cells that embed themselves in tissues, including diseased kidneys, and continue producing autoantibodies even when other B cells are suppressed by treatment. These long-lived plasma cells are resistant to standard therapies, which partly explains why lupus is so difficult to put into lasting remission.
Kidney Damage as the Classic Example
Lupus nephritis, the kidney inflammation that occurs in a significant proportion of lupus patients, is the textbook example of type 3 hypersensitivity in action. Anti-dsDNA antibodies bind to DNA and form immune complexes that deposit in specific locations within the kidney’s filtering units: the mesangium, the subendothelial space, or the subepithelial space near the glomerular basement membrane. Some autoantibodies also bind directly to antigens already present on the glomerular basement membrane, forming complexes right where they sit.
Either way, the result is the same. Complement activation brings in waves of inflammatory cells, and the resulting damage impairs the kidney’s ability to filter blood properly. Doctors track this process by measuring complement proteins C3 and C4 in the blood. Because these proteins are consumed during the inflammatory cascade, their levels drop when lupus is active. Normal C3 ranges from 80 to 178 mg/dl, and during a kidney flare it typically drops to around 70 mg/dl. C4, normally 12 to 42 mg/dl, falls to around 11.5 mg/dl in the months before a flare, making it a useful early warning sign. Rising anti-dsDNA antibody levels alongside falling complement levels is one of the most reliable patterns for predicting a flare.
Skin and Blood Vessel Involvement
Immune complex deposition doesn’t stop at the kidneys. When complexes lodge in blood vessel walls, they cause lupus vasculitis. Biopsies of affected skin show a characteristic pattern: neutrophils infiltrate the vessel wall, their nuclei fragment (a pattern called leukocytoclasia), and the vessel wall itself undergoes fibrinoid necrosis, essentially dissolving under the enzymatic assault. The overlying skin and sweat glands sustain secondary damage. In more severe cases, vessel damage leads to blood clots, vessel blockage, hemorrhage, and tissue death from loss of blood supply.
In the kidneys, true renal vasculitis shows a similar picture. Neutrophils and other immune cells infiltrate the inner and middle layers of vessel walls, sometimes with fibrinoid necrosis and destruction of the elastic tissue that gives vessels their structure. This vascular damage compounds the direct glomerular injury from immune complex deposition.
Lupus Also Involves Type 2 Hypersensitivity
While type 3 hypersensitivity dominates the overall disease, certain lupus complications operate through type 2 mechanisms. In type 2 hypersensitivity, antibodies bind directly to the surface of specific cells, marking them for destruction. This is what happens when lupus causes autoimmune hemolytic anemia, where antibodies coat red blood cells and immune cells destroy them, leading to anemia. The same mechanism drives immune thrombocytopenia in lupus, where antibodies target platelets and cause dangerously low platelet counts.
This dual nature is important. The kidney inflammation, vasculitis, joint pain, and many other classic lupus symptoms are driven by type 3 immune complex deposition. But the blood cell destruction that some lupus patients experience is a separate type 2 process, with antibodies attacking cells directly rather than forming circulating complexes. Both mechanisms involve autoantibodies, but they damage the body in fundamentally different ways. This is why lupus can look so different from one patient to the next: the specific mix of hypersensitivity reactions shapes which organs are affected and how.
How This Shapes Treatment
Understanding lupus as primarily a type 3 hypersensitivity disease explains the logic behind its treatment strategies. Therapies that suppress B cell activity aim to reduce the production of the autoantibodies that form immune complexes in the first place. Immunosuppressive medications broadly dial down the inflammatory response that immune complexes trigger once deposited. Physically filtering immune complexes from the blood through plasmapheresis has been studied, but clinical trials in severe lupus nephritis have not shown it to be effective enough to recommend as a standard approach.
The persistence of long-lived plasma cells in tissues also explains a frustrating clinical reality: even when B cells in the blood are depleted by treatment, autoantibody production can continue from these entrenched cells. This is an active area of focus in developing more effective lupus therapies, since eliminating the source of immune complexes remains the most logical way to interrupt the type 3 hypersensitivity cycle at its root.